Yarrow Supercritical Extract Exerts Antitumoral Properties by Targeting Lipid Metabolism in Pancreatic Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2019 Mar 27

PMID 30913248

Citations 8

Authors

Lamia Mouhid

Marta Gomez de Cedron

Elena Garcia-Carrascosa

Guillermo Reglero

Tiziana Fornari

Ana Ramirez de Molina

Affiliations

Soon will be listed here.

Abstract

Metabolic reprogramming is considered a hallmark of cancer. Currently, the altered lipid metabolism in cancer is a topic of interest due to the prominent role of lipids regulating the progression of various types of tumors. Lipids and lipid-derived molecules have been shown to activate growth regulatory pathways and to promote malignancy in pancreatic cancer. In a previous work, we have described the antitumoral properties of Yarrow (Achillea Millefolium) CO2 supercritical extract (Yarrow SFE) in pancreatic cancer. Herein, we aim to investigate the underlaying molecular mechanisms by which Yarrow SFE induces cytotoxicity in pancreatic cancer cells. Yarrow SFE downregulates SREBF1 and downstream molecular targets of this transcription factor, such as fatty acid synthase (FASN) and stearoyl-CoA desaturase (SCD). Importantly, we demonstrate the in vivo effect of Yarrow SFE diminishing the tumor growth in a xenograft mouse model of pancreatic cancer. Our data suggest that Yarrow SFE can be proposed as a complementary adjuvant or nutritional supplement in pancreatic cancer therapy.

Citing Articles

Randomized clinical trial in cancer patients shows immune metabolic effects exerted by formulated bioactive phenolic diterpenes with potential clinical benefits.

Gomez de Cedron M, Moreno-Rubio J, de la O Pascual V, Alvarez B, Villarino M, Sereno M Front Immunol. 2025; 16:1519978.

PMID: 40034703 PMC: 11872936. DOI: 10.3389/fimmu.2025.1519978.

Targeting lipid metabolism: novel insights and therapeutic advances in pancreatic cancer treatment.

Zhang Y, Yang Z, Liu Y, Pei J, Li R, Yang Y Lipids Health Dis. 2025; 24(1):12.

PMID: 39806478 PMC: 11727729. DOI: 10.1186/s12944-024-02426-0.

Novel bioactive extract from yarrow obtained by the supercritical antisolvent-assisted technique inhibits lipid metabolism in colorectal cancer.

Gomez de Cedron M, Siles-Sanchez M, Martin-Hernandez D, Jaime L, Santoyo S, Ramirez de Molina A Front Bioeng Biotechnol. 2024; 12:1256190.

PMID: 38576446 PMC: 10991822. DOI: 10.3389/fbioe.2024.1256190.

The role of metabolic reprogramming in pancreatic cancer chemoresistance.

Liu C, Li C, Liu Y Front Pharmacol. 2023; 13:1108776.

PMID: 36699061 PMC: 9868425. DOI: 10.3389/fphar.2022.1108776.

Active Biomolecules from Vegetable Extracts with Antitumoral Activity against Pancreas Cancer: A Systematic Review (2011-2021).

Mesas C, Quinonero F, Doello K, Revueltas J, Perazzoli G, Cabeza L Life (Basel). 2022; 12(11).

PMID: 36362920 PMC: 9695035. DOI: 10.3390/life12111765.

References

Mouhid L, Gomez de Cedron M, Vargas T, Garcia-Carrascosa E, Herranz N, Garcia-Risco M . Identification of antitumoral agents against human pancreatic cancer cells from Asteraceae and Lamiaceae plant extracts. BMC Complement Altern Med. 2018; 18(1):254. PMC: 6142333. DOI: 10.1186/s12906-018-2322-6. View

Cao M, Yie S, Liu J, Ye S, Xia D, Gao E . Plasma soluble HLA-G is a potential biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer. Tissue Antigens. 2011; 78(2):120-8. DOI: 10.1111/j.1399-0039.2011.01716.x. View

Yang Z, Zhuang L, Szatmary P, Wen L, Sun H, Lu Y . Upregulation of heat shock proteins (HSPA12A, HSP90B1, HSPA4, HSPA5 and HSPA6) in tumour tissues is associated with poor outcomes from HBV-related early-stage hepatocellular carcinoma. Int J Med Sci. 2015; 12(3):256-63. PMC: 4366630. DOI: 10.7150/ijms.10735. View

Hansel D, Rahman A, Wilentz R, Shih I, McMaster M, Yeo C . HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract. Int J Gastrointest Cancer. 2005; 35(1):15-23. DOI: 10.1385/ijgc:35:1:015. View

Blum R, Kloog Y . Metabolism addiction in pancreatic cancer. Cell Death Dis. 2014; 5:e1065. PMC: 3944253. DOI: 10.1038/cddis.2014.38. View

Aguirre-Ghiso J . Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007; 7(11):834-46. PMC: 2519109. DOI: 10.1038/nrc2256. View

Liu J, Ma J, Wu Z, Li W, Zhang D, Han L . Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling. BMC Cancer. 2014; 14:686. PMC: 4189535. DOI: 10.1186/1471-2407-14-686. View

Swierczynski J, Hebanowska A, Sledzinski T . Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. World J Gastroenterol. 2014; 20(9):2279-303. PMC: 3942833. DOI: 10.3748/wjg.v20.i9.2279. View

Hall W, Petrova A, Colbert L, Hardy C, Fisher S, Saka B . Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer. Oncogene. 2013; 33(47):5450-6. DOI: 10.1038/onc.2013.488. View

10.

Li W, Tai Y, Zhou J, Gu W, Bai Z, Zhou T . Repression of endometrial tumor growth by targeting SREBP1 and lipogenesis. Cell Cycle. 2012; 11(12):2348-58. PMC: 3383594. DOI: 10.4161/cc.20811. View

11.

Long X, Hua Mao J, Peng A, Zhou Y, Huang S, Liu Z . Tumor suppressive microRNA-424 inhibits osteosarcoma cell migration and invasion via targeting fatty acid synthase. Exp Ther Med. 2013; 5(4):1048-1052. PMC: 3628901. DOI: 10.3892/etm.2013.959. View

12.

Deisenroth C, Itahana Y, Tollini L, Jin A, Zhang Y . p53-Inducible DHRS3 is an endoplasmic reticulum protein associated with lipid droplet accumulation. J Biol Chem. 2011; 286(32):28343-56. PMC: 3151078. DOI: 10.1074/jbc.M111.254227. View

13.

Uckun F, Qazi S, Ozer Z, Garner A, Pitt J, Ma H . Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network. Br J Haematol. 2011; 153(6):741-52. DOI: 10.1111/j.1365-2141.2011.08671.x. View

14.

Eberle D, Hegarty B, Bossard P, Ferre P, Foufelle F . SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 2004; 86(11):839-48. DOI: 10.1016/j.biochi.2004.09.018. View

15.

Phillips M, Sheaff M, Szlosarek P . Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat. 2014; 45(4):251-62. PMC: 3893322. DOI: 10.4143/crt.2013.45.4.251. View

16.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

17.

Niu Z, Liu Q, Wang M, Zhou L, Yao L, Liao Q . Changes in the Expression of Glucose-regulated Protein 78 in the Occurrence and Progression of Pancreatic Cancer in Mouse Models. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2015; 37(3):259-63. DOI: 10.3881/j.issn.1000-503X.2015.03.002. View

18.

Nazemalhosseini-Mojarad E, Kuppen P, Zali M . Human Leukocyte antigen-G (HLA-G) and gastrointestinal malignancy. Gastroenterol Hepatol Bed Bench. 2014; 7(2):79-81. PMC: 4017564. View

19.

Kloth J, Gorter A, Fleuren G, Oosting J, Uljee S, Ter Haar N . Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma. J Pathol. 2008; 215(3):222-30. DOI: 10.1002/path.2347. View

20.

Zhao R, Yan Q, Lv J, Huang H, Zheng W, Zhang B . CHD5, a tumor suppressor that is epigenetically silenced in lung cancer. Lung Cancer. 2011; 76(3):324-31. DOI: 10.1016/j.lungcan.2011.11.019. View